| |
著者: Robert H Gelber, Victoria F Balagon, Roland V Cellona
雑誌名: Int J Lepr Other Mycobact Dis. 2004 Dec;72(4):493-500. doi: 10.1489/1544-581X(2004)72<493:TRRIML>2.0.CO;2.
Abstract/Text
A group of multibacillary patients is clearly at high risk for relapse following 2-yr WHO-MDT. Relapse is largely confined to BL or LL patients with a high BI initially, and occurs long after the discontinuation of therapy. This important group of patients at risk for treatment failure presents several important issues: the need to identify those at risk and the operational requirements needed for their long term follow-up. Also, this group of patients might well benefit from an alternative antimicrobial regimen from the outset, as well as upon relapse.
PMID 15755209 Int J Lepr Other Mycobact Dis. 2004 Dec;72(4):493-500. doi: 10.1489/1544-581X(2004)72<493:TRRIML>2.0.CO;2.
|
